It is a new day for cancer research and for
cancer patients. Rapidly evolving technology is enabling extraordinary advances
in cancer research that deepen our understanding of how cancer develops, grows
and threatens the lives of millions. By exploiting this growing body of
knowledge about cancer biology, we can be more strategic and innovative than
ever before in the way we attack cancer. This is quickening the pace of
developing new ways to prevent, detect, diagnose and treat cancer.The AACR
Cancer Progress Report 2012 celebrates the many ways that we have made research
count for cancer patients, particularly in the past year alone. Decades of
research, in large part thanks to our Nation's long-standing investment in
cancer research and biomedical science by the National Institutes of Health
(NIH) and the National Cancer Institute (NCI), have provided the foundation for
the progress that is helping usher in this new day for patients with many forms
of cancer.Highlighted in this Report are treatment advances approved by the
U.S. Food and Drug Administration (FDA) in the past 12 months alone, including:
1) a new drug for treating precancerous lesions of the skin; 2) eight new drugs
for treating a variety of types of cancer, of which two are entirely new
classes of drugs; 3) four new uses for previously approved cancer drugs, one of
the four uses being an alternative administration to reduce side effects. The
Report also presents new discoveries that are forming the foundation of
tomorrow's progress.As a reminder of why it is so critical for the Nation to
prioritize cancer research and biomedical science, the 2012 Report describes
the exciting research progress and scientific opportunities ahead. Also, to put
a face on the realities of cancer, we have chronicled the experiences and the
sentiments of twelve cancer survivors, and as well as a mother and father who
suffered unimaginable grief when their seven-year-old child died of
neuroblastoma.
Source: AACR Cancer Progress Report
2012. AACR Cancer Progress Report Writing Committee. Clin Cancer Res. 2012 Sep
11.
Free paper available at:
Aucun commentaire:
Enregistrer un commentaire